* HME360, the only SaaS-based inventory optimisation platform created by HME providers for HME providers, has published a new industry study entitled Inventory and Asset Management Gaps in the HME|DME Industry.
The research, carried out by in90group Research, an independent firm specialising in healthcare industry analysis, highlights that outdated manual processes are costing HME|DME providers more than $4 billion each year through wasted labour, missed revenue, and tied-up cash flow.
Key findings from the report include:
* Annual losses exceeding $4 billion caused by excess stock, asset shrinkage, wasted staff hours, and missed sales.
*Almost 90% of providers continue to rely on routine manual counts, creating staff dissatisfaction and inefficiencies.
* 65% of providers admit to losing revenue opportunities because of poor inventory management.
* Fewer than 1 in 10 executives believe their inventory systems are operating at full effectiveness.
The study also outlines what HME leaders see as the main drivers of inventory optimisation, offering a clear path for providers seeking to replace disorder with control.
"Inventory inefficiency has become a strategic risk for HME providers," said John Skoro, Co-Founder and CEO of HME360. "Manual processes and outdated systems are draining the industry. But there is a path forward – automation, integration, and visibility are the keys to turning inventory into a strategic advantage."
"This report validates what we've been hearing from providers for years," added Bryan Hines, Co-Founder and President of HME360. "They know inventory is out of control, but they've lacked the tools and visibility to fix it. With the data in this report, leaders now have a baseline – and a roadmap – for how to finally take control."
The full report, released today on the HME360 website, gives detailed insight into where financial losses occur and how True Automation can enable providers to eliminate inefficiencies, establish inventory control, and drive business growth.
To download the full report, visit: hme360.com.
source:newsreleases.co.uk
Relay Therapeutics wins FDA breakthrough status for zovegalisib in breast cancer treatment
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Valneva and Instituto Butantan launch pilot chikungunya vaccination campaign in Brazil
Lupin launches Dasatinib tablets in US market
WuXi Biologics enters into licence and research service agreement with Vertex Pharmaceuticals
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Astrazeneca Imfinzi perioperative regimen gains positive EU CHMP opinion in early gastric cancer
I Peace generates human iPS cells from NKT cells and offers them for research use
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
AstraZeneca agrees obesity and type 2 diabetes collaboration with CSPC
Ascletis Pharma Inc reports topline results from Phase III open-label study of denifanstat
Innovative Molecules GmbH completes Phase 1 clinical development programme for adibelivir
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA